@heloix_news
Funding

Rodrica Michael

Bengaluru-based biotechnology startup Venomics AI has raised $2.7 million in a pre-seed funding round to strengthen its research and develop its AI-powered drug discovery platform.
The funding marks the company's first institutional investment. The round was co-led by Speciale Invest and South Park Commons, with participation from Operators Studio.
The company plans to use the fresh capital to expand its operations, build a larger molecular dataset and improve its artificial intelligence and laboratory screening capabilities.
Combining Venom Research with Artificial Intelligence
Founded in May 2026 by Sunagar and Vinay Prabhu, Venomics AI focuses on discovering potential drug candidates using venom biology, molecular sequencing, artificial intelligence and laboratory-based research.
The startup is developing a platform called Venom Atlas, which brings together molecular information derived from animal venoms and experimental laboratory testing.
Through this platform, the company uses AI to identify and prioritise promising molecular candidates. These predictions are then tested through laboratory screening, with the results helping improve future predictions and molecular designs.
Venomics AI aims to use India's rich venom biodiversity, along with its scientific and computational capabilities, to develop potential treatments for a range of medical conditions.
Building Its Research and Development Capabilities
The company has already established the initial framework of its platform and joined the NVIDIA Inception programme. It was also selected as one of the top five finalists for the 2026 Indo-Boston Biotech Bridge Award.
With the latest funding, Venomics AI plans to expand its team by bringing together specialists in venom biology, computational science and drug discovery.
It will also focus on testing and improving promising molecules to determine their potential for future therapeutic applications.
Venom-Based Drug Discovery Gains Attention
Animal venoms contain bioactive peptides and proteins that researchers are studying for their potential medical applications.
Molecules found in snake, scorpion and marine animal venoms could offer opportunities for developing treatments for pain management, neurological conditions, cardiovascular diseases and other health-related areas.
Venomics AI is not the only startup exploring this field. Snaayu Lifesciences, which is incubated at C-CAMP, is working on identifying and studying new pain-relieving compounds found in cone snail venom.
AI Continues to Attract Investment in Drug Discovery
Interest in artificial intelligence-driven drug discovery has also been growing among investors.
In February 2026, Bengaluru-based Peptris Technologies raised Rs 70 crore in a Series A funding round co-led by IAN Alpha Fund and Speciale Invest.
The company uses AI-based molecular discovery and experimental testing to identify and develop potential drug candidates.
With its latest funding, Venomics AI aims to strengthen its research capabilities and build a platform that connects India's biodiversity with advanced drug discovery technology.
As the company expands its molecular database and laboratory capabilities, its progress will be worth watching in the emerging field of AI-powered biotechnology.
โปรด เพื่อแสดงความคิดเห็น
ยังไม่มีความคิดเห็น
ร่วมแสดงความคิดเห็นเป็นคนแรก
@heloix_news
Funding

@heloix_news
Funding

@heloix_news
Funding

ติดตามข้อมูลล่าสุดเกี่ยวกับเทคโนโลยี การเติบโตทางธุรกิจ และการเปลี่ยนผ่านสู่ดิจิทัล